Brigatinib (BRG) in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): updates from a phase 1/2 trial

Authors
Category Primary study
JournalJournal of clinical oncology
Year 2017
This article has no abstract
Epistemonikos ID: bc82092f9021dd20d694b44191e8623d6d8c13a9
First added on: Feb 08, 2025